New Products

BOCA RATON, Fla. — STUF Men’s Defense, a skin care line just for guys, has announced that it is now being sold on Amazon.com.

Commissioned by 11-time Olympic medalist Mark Spitz, STUF Men’s Defense is made from naturally produced ingredients, including combinations of herbs, antioxidants and vitamins, and the products do not contain any animal byproducts, mineral oils, parabens, colorants or phthalates.

ARMONK, N.Y. — The University of Arizona College of Pharmacy is switching from a MacOS-based platform to an IBM system running Linux to manage growth of big data.

IBM said Wednesday that the Tucson, Ariz., college was using an IBM zEnterprise mainframe running the IBM DB2 database software on Linux to analyze and process 3 million medical claims per week. A business partner of IBM, Sirius Computer Solutions, helped the college move to the new system, which reduces the time it takes to process medical claims by 60%.

DEERFIELD, Ill. — The Food and Drug Administration has approved a drug made by Lundbeck for treating a form of epilepsy in children, the drug maker said.

Lundbeck announced the approval of Sabril (vigabatrin) as an add-on therapy for refractory complex partial seizures in children ages 10 years and older who have not responded adequately to other treatments, as long as the benefit of treatment outweighs the risk of vision loss. The drug was already approved for treating the same condition in adults in 2009.

BOCA RATON, Fla. — MelanSol, an all-natural sunscreen brand, has announced that it is working to expand the availability of its products across the United States.

DUBLIN — Actavis hopes to become the first company to market a generic version of a drug used to treat acne in adolescents and adults, the company said.

The drug maker announced that it had filed a regulatory approval application with the Food and Drug Administration for a generic version of Acanya (clindamycin phosphate; benzoyl peroxide) gel in the 1.2%/2.5% strength. Acanya is made by Valeant Pharmaceuticals International and Dow Pharmaceutical Sciences and is used to treat acne vulgaris in patients aged 12 and older.

NEW YORK — Generic drug maker Amneal Pharmaceuticals is seeking Food and Drug Administration approval for a gout drug, prompting a lawsuit from the maker of the branded version, according to published reports.

Law360 reported that Takeda Pharmaceuticals USA had sued Amneal in the U.S. District Court for the District of Delaware over the drug Colcrys (colchicine), used to treat gout and familial Mediterranean fever.

OAK BROOK, Ill. — Blistex expanded its product portfolio in October with the launch of two new lip balms — Nurture and Nourish and Lip Vibrance.

NEWARK, Calif. — Depomed has launched a new drug for breakthrough pain in cancer patients, the company said Monday.

The drug maker announced the launch of Lazanda (fentanyl) nasal spray, meant for treating adults who are taking opioid painkillers, but have become tolerant to them. The company also have launched a Signature Support Program designed to streamline patient access to the drug, including reimbursement and co-pay assistance. Other benefits of the program include prescription reminders and eligibility for one month's supply for free.